Get the Stockscreener App
0.7759
2.27%
-0.018
Pre-market:
.78
0.0041
+0.53%
Adicet Bio Inc stock is traded at $0.7759, with a volume of 136.88K.
It is down -2.27% in the last 24 hours and down -13.74% over the past month.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
See More
Previous Close:
$0.7939
Open:
$0.7737
24h Volume:
136.88K
Relative Volume:
0.17
Market Cap:
$64.16M
Revenue:
$38.70M
Net Income/Loss:
$-117.88M
P/E Ratio:
-0.4564
EPS:
-1.7
Net Cash Flow:
$-92.84M
1W Performance:
-8.29%
1M Performance:
-13.74%
6M Performance:
-47.93%
1Y Performance:
-65.52%
1-Day Range:
$0.7582
$0.798
1-Week Range:
$0.745
$0.8505
52-Week Range:
$0.745
$2.43
Adicet Bio Inc Stock (ACET) Company Profile
Name
Adicet Bio Inc
Sector
Industry
Phone
617-482-2333
Address
131 DARTMOUTH STREET, BOSTON
Compare ACET with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
0.7759 | 64.16M | 38.70M | -117.88M | -92.84M | -1.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-24 | Resumed | Guggenheim | Buy |
| Sep-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-27-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Mar-31-22 | Initiated | SMBC Nikko | Outperform |
| Mar-08-22 | Initiated | Truist | Buy |
| Mar-04-22 | Initiated | Jefferies | Buy |
| May-18-21 | Initiated | BTIG Research | Buy |
| Apr-23-21 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Canaccord Genuity | Buy |
| Apr-08-21 | Initiated | Guggenheim | Buy |
| Nov-04-20 | Initiated | B. Riley Securities | Buy |
| Oct-27-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-16-20 | Initiated | Wedbush | Outperform |
View All
Adicet Bio Inc Stock (ACET) Latest News
Adicet Bio’s SWOT analysis: gamma-delta T cell stock faces pivotal year - Investing.com India
Adicet Bio (ACET) Expected to Announce Earnings on Tuesday - Defense World
Promising Pipeline and Strong Financials Drive Buy Rating for Adicet Bio - TipRanks
Adicet Bio (NASDAQ:ACET) Earns “Neutral” Rating from HC Wainwright - Defense World
Adicet Bio Advances Clinical Trials and Financial Stability - TipRanks
H.C. Wainwright maintains Neutral on Adicet Bio stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Neutral on Adicet Bio stock - Investing.com India
Cautious Hold Rating on Adicet Bio Amid Early-Stage Clinical Developments and Uncertain Outcomes - TipRanks
Adicet Bio: Hold Rating Amid Fair Valuation and Awaited Clinical Data - TipRanks
Adicet Bio Inc Files For Mixed Shelf Of Up To $250 Million -March 06, 2025 at 04:59 pm EST - Marketscreener.com
Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress - Lelezard
Adicet Bio, Inc Q4 Loss Decreases - Nasdaq
Adicet Bio reports Q4 EPS (32c), consensus (35c) - TipRanks
Can Adicet Bio's $176M War Chest and Fast Track Status Transform Autoimmune Treatment? - StockTitan
Adicet Bio, Inc. (NASDAQ:ACET) Receives $7.50 Average Target Price from Analysts - Defense World
Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Update - Defense World
Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting - Business Wire
Can Adicet's Novel CAR T Therapy Revolutionize Renal Cancer Treatment? New Data Coming - StockTitan
Adicet Bio's (ACET) "Neutral" Rating Reaffirmed at HC Wainwright - MarketBeat
Adicet Bio shares rise on FDA Fast Track Designation for ADI-001 - Investing.com
FDA fast tracks Adicet Bio's autoimmune therapy By Investing.com - Investing.com South Africa
FDA fast tracks Adicet Bio’s autoimmune therapy - Investing.com
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc) - Lelezard
FDA fast tracks Adicet Bio’s autoimmune therapy By Investing.com - Investing.com UK
Adicet's Systemic Sclerosis Therapy Earns Critical FDA Fast Track StatusWhat This Means for Patients - StockTitan
Adicet Bio (NASDAQ:ACET) versus Corvus Pharmaceuticals (NASDAQ:CRVS) Head to Head Analysis - Defense World
Adicet Bio's SWOT analysis: gamma-delta T cell stock faces pivotal year By Investing.com - Investing.com South Africa
Adicet Bio's SWOT analysis: gamma-delta T cell stock faces pivotal year - Investing.com
Healthy Upside Potential: Adicet Bio Inc (ACET) - SETE News
Adicet Bio Inc [ACET] Insider Activity: An Update for Investors - Knox Daily
Investor Alert: What’s Really Going On At Adicet Bio Inc (NASDAQ: ACET) - Stocks Register
Adicet Bio (NASDAQ:ACET) Earns Market Perform Rating from JMP Securities - MarketBeat
Brokerages Set Adicet Bio, Inc. (NASDAQ:ACET) PT at $7.50 - MarketBeat
Adicet Bio reports progress in clinical trial enrollments - MSN
HC Wainwright Reaffirms Neutral Rating for Adicet Bio (NASDAQ:ACET) - MarketBeat
Adicet Bio (NASDAQ:ACET) Earns “Market Perform” Rating from JMP Securities - Defense World
Top investors say Adicet Bio Inc (ACET) ticks everything they need - SETE News
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease - geneonline
Adicet Bio Inc [NASDAQ: ACET] Sees Increase in Stock Value - Knox Daily
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Invest In Growth? - Simply Wall St
Adicet Bio reports progress in clinical trial enrollments By Investing.com - Investing.com Australia
Adicet Bio Inc (ACET) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Adicet Bio Inc (ACET) Stock Price and Analyst Predictions - The News Heater
What is ACET’s price-to-sales ratio telling us about the company’s value? - US Post News
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement - Marketscreener.com
Revolutionary Lupus Treatment Gets FDA Fast-Track: Adicet's ADI-001 Could Transform Patient Care - StockTitan
JPMorgan Chase & Co. Boosts Stock Holdings in Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
Adicet Bio Sparks Excitement with Major Stock Options Award for New Hires! - Mi Valle
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Adicet Bio Inc Stock (ACET) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):